News

Latest news

Hide mandatory notifications of trade

Bionor Pharma ASA issues share options to three key consultants

Oslo 18.06.2013 - The Board of Directors in Bionor Pharma ASA has approved anew stock option program for 3 consultants as part of an incentive program foremployees and consultants in Bionor Pharma.

The program issues 600,000 options and has three years vesting period. The
options are exercisable at a price of NOK 3.50 per share, equivalent to the
closing share price on 17 June 2013. The options vest by 1/3 on 1 June
2014, 1/3 on 1 June 2015 and remaining 1/3 on 1 June 2016.

The share options can be issued according to the power of attorney from the
General Meeting on 15 May 2013 to issue up to 12 million options to employees
and consultants whose advisory is vital to the Company. The total number of
outstanding share options in Bionor Pharma is now 9.22 million.

The following consultants have been granted options in this program:

Prof. Angus Dalgleish has received 200,000 options. Following the receipt of
the options Prof. Angus Dalgleish holds 0 shares and 200,000 options in Bionor
Pharma ASA.

Alison Blakey has received 200,000 options. Following the receipt of the options
Alison Blakey holds 0 shares and 200,000 options in Bionor Pharma ASA.

Gill Pearce has received 200,000 options. Following the receipt of the options
Gill Pearce holds 0 shares and 200,000 options in Bionor Pharma ASA.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Contact information

Bionor Pharma ASA, Oslo: +47 23 01 09 60

Synne H. Røine, CFO

Hilde Aalling Syvertsen, Director Communications & Corporate Affairs